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Abstract
Purpose The aim of this study was to conWrm the expres-
sion proWle of cytokeratin (CK)17 in comparison with that
of CK13 in oral squamous cell carcinoma (OSCC) and leu-
koplakia and to clarify an association of CK17 with the
OSCC diVerentiation.
Materials The expression of CK17 and CK13 was immu-
nohistochemically examined in 105 patients with OSCC
and 108 patients with leukoplakia. A correlation of CK
expression with clinicopathological variables was carried
out. The over-expression levels of CK17 mRNA were ana-
lyzed by real-time RT-PCR in 5 OSCC cell lines (HSC-2,
HSC-3, SAS, SQUU-A, SQUU-B).
Results CK17 and CK13 were detected in 101 (96.2 %)
and three (2.9 %) of the 105 OSCCs, respectively. CK17
was signiWcantly expressed in well-diVerentiated OSCC
compared to moderately/poorly diVerentiated OSCC
(p < 0.01). As detected in 19 of the 34 dysplastic leukoplak-
ias (55.9 %) and 36 of the 74 hyperplastic leukoplakias
(48.6 %), CK17 was signiWcantly expressed in dysplastic
leukoplakias (p < 0.01). As detected in 11 of the 34 dys-
plastic (32.4 %) and 52 of the 74 hyperplastic leukoplakias
(70.3 %), CK13 was signiWcantly expressed in hyperplastic
leukoplakias (p < 0.01). The relative expression of CK17
mRNA in HSC-2 was signiWcantly higher than in HSC-3
and SAS (p < 0.05). Moreover, the relative expression of
CK17 mRNA in SQUU-A was signiWcantly higher than in
SQUU-B (p < 0.05).
Conclusion CK17 expression could be associated with
the diVerentiation and the malignancy of OSCC. A combi-
nation pattern of CK17/CK13 might be a suitable marker of
malignant transformation.
Keywords Cytokeratin 17 · Oral squamous cell 
carcinoma · Leukoplakia · DiVerentiation · 
Cytokeratin 13 · Immunohistochemistry
Introduction
Despite diagnostic and therapeutic advances by introducing
combination therapy including surgery, radiotherapy, and
chemotherapy, the 5-year survival rate of oral squamous
cell carcinoma (OSCC) remains 70–80 % (Gorsky et al.
2004; Sasaki et al. 2011), because of the late-stage diagno-
sis and the resistance to radiotherapy or chemotherapy. For
early diagnosis and individual therapy of the patients, it is
of great importance to Wnd out diagnostic markers of
OSCC. Cytokeratins (CKs), intermediate Wlament of the
cytoskeletons, are candidates for diagnostic markers of
OSCC, as they are over-expressed in OSCC compared to
normal mucosa (Xu et al. 1995). Biochemical and immuno-
histochemical studies have indicated that OSCC expresses
a wider range of CKs than normal epithelium, because
cancerization of normal oral epithelium could lead to varia-
tion of diVerentiation degree (Wetzels et al. 1992).
Among CKs, CK17 should be focused as a diagnostic
marker of OSCC, since several studies have reported that
the expression of CK17 could be detected in malignant tis-
sues compared to normal tissues in squamous cell carci-
noma of lung (Wetzels et al. 1992), cervix (Carrilho et al.
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and esophagus (Takahashi et al. 1995; Luo et al. 2004). In
oral cavity, our previous study based on the microarray and
the real-time RT-PCR analyses have reported that the sig-
niWcant up-regulation and the strong over-expression of
CK17 could exhibit the utility as diagnostic marker of
OSCC (Toyoshima et al. 2008). Focused on diVerentiation
of cells expressing CK17, CK17 is also considered as a
marker of basal cell diVerentiation to distinguish columnar
epithelium from squamous epithelium in cervix (Martens
et al. 2004). Moreover, CK17 is markedly expressed in
well-diVerentiated squamous cell carcinoma (Carrilho et al.
2004). However, to our knowledge, a paucity of material is
available on a correlation between the CK17 expression
and the diVerentiation in OSCC.
CK13 is mucosa speciWc and expressed in the suprabasal
layers of non-keratinized stratiWed epithelia. In normal
tissue, CK13 is usually expressed in the conjunctival and
limbal epithelium (Ramirez-Miranda et al. 2011). On the
contrary, decreasing of CK13 expression is found in dys-
plastic lesions in the oral epithelium and associated with the
development of OSCC and oral leukoplakia (Ohta et al.
2010). Because of the loss of stratiWcation, CK13 is down-
regulated in malignant lesion (Bloor et al. 2000). Carrilho
et al. (2004) have reported that the expression of CK17 and
the loss of CK13 are appropriate markers of malignant
transformation in cervix carcinoma. In addition, Whipple
et al. (2004) have reported that CK17 mRNA is up-regu-
lated, while CK13 mRNA is down-regulated in OSCC by
the microarray analyses. Moreover, it has been reported
that CK17 is signiWcantly up-regulated in leukoplakia and
is absent in normal oral epithelium (Mikami et al. 2011). In
contrast, CK13 is down-regulated in leukoplakia and Wrmly
expressed in normal oral epithelium. However, little is
known about an association of CK17 and CK13 expres-
sions with the diVerentiation of OSCC and leukoplakia.
Therefore, the aim of this study was to conWrm the
immunohistochemical proWle of CK17 in comparison with
that of CK13 in OSCC, leukoplakia, and normal oral epi-
thelium from a diVerentiation point of view. Secondly, we
focused on CK17 mRNA expression in OSCC cell lines in




One hundred and Wve patients with primary OSCC and 108
patients with primary leukoplakia, diagnosed at the Depart-
ment of Oral and Maxillofacial Surgery, Kyushu University
Hospital, from 2005 to 2008, were enrolled in this study.
Ten control cases (normal oral epithelium) were also
enrolled. Patients’ informed consent and the approval of the
local ethical committee were given. Following the initial
biopsy, all specimens were Wxed in 4 % buVered formalin
solution and embedded in paraYn blocks. Subsequently,
the paraYn-embedded specimens were processed to 5-m-
thick sections, stained with hematoxylin–eosin (HE), and
examined by three experienced pathologists to conWrm the
diagnoses and the histological grades. The histological
grade in the OSCC and the degree of epithelial dysplasia in
the leukoplakia were assessed according to the World
Health Organization classiWcation (Gale et al. 2005; Wahi
et al. 1977). The tumor extent and the clinical stages were
evaluated according to the TNM classiWcation established
by the American Joint Committee on Cancer and the Inter-
national Union Against Cancer (UICC) (Sobin and Witte-
kind 2002). The mode of invasion was also determined on
Table 1 Characteristics of 105 patients with OSCC
Characteristics Category Cases (%)
Gender Male 53 (50.5)
Female 52 (49.5)
Age 65> 61 (61.0)
65< 44 (39.0)
Alcohol Yes 56 (53.3)
No 49 (46.7)
Smoking Yes 48 (45.7)
No 57 (52.3)
DiVerentiation Well 72 (68.6)
Moderate 31 (29.5)
Poor 2 (1.9)




N Positive 20 (19.0)
Negative 85 (81.0)









Localization of the lesion Tongue 63 (60.0)
Gingiva 23 (21.9)
Buccal mucosa 8 (7.6)
Floor of mouth 7 (6.7)
Palate 4 (3.8)123
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Kohama’s criteria, as follows: grade 1 = well-deWned bor-
derline; grade 2 = cords, less-marked borderline; grade
3 = group of cells, no distinct borderline; grade 4 = diVuse
invasion, 4C: cord-like type; 4D: widespread type
(Yamamoto et al. 1984). Medical records were reviewed to
collect the information concerning the clinical characteris-
tic. The detailed clinical data of the patients with OSCC
and leukoplakia are presented in Tables 1 and 2.
Immunohistochemistry
Immunohistochemical staining was performed on 5-m-
thick sections sliced serially from paraYn-embedded
blocks after formalin Wxation of the excised specimens. The
sections were deparaYnized in xylene and rehydrated in a
graded series of ethanol/water concentrations (100, 95, 90,
85, and 75 %). For antigen retrieval, the sections were
immersed in DAKO Target Retrieval Solution (Dako Cyto-
mation, Denmark) and autoclaved at 120 °C for 5 min. The
endogenous peroxide activity was then eliminated with 1 %
hydrogen peroxide for 30 min, and the section was rinsed
twice for 10 min with phosphate-buVered saline (PBS) at
pH 7.4. Non-speciWc protein binding was blocked by incu-
bation for 1 h with 10 % goat serum, and then, the sections
were incubated with each primary antibody for 3 h at room
temperature. The following primary antibodies were used:
anti-human monoclonal CK17 antibody (clone E3, Dako
Cytomation, Denmark; diluted 1:60) and anti-human mono-
clonal CK13 antibody (clone KS-1A3, Novocastra,
Germany; diluted 1:1000). The sections were rinsed twice
for 10 min with PBS and incubated with secondary anti-
bodies conjugated with peroxidase-labeled amino acid
polymer for 1 h at room temperature. After rinsing with
PBS twice for 10 min, the immunoreactivity was visualized
by immersing the sections in 3, 3-diaminobenzidine and
0.6 % hydrogen peroxide (DAB substrate kit, Nichirei,
Japan). Subsequently, the sections were counterstained
with Mayer’s hematoxylin, dehydrated in graded ethanol
(75, 85, 90, 95 and 100 %), cleared with xylene, and Wnally
mounted with permanent mounting medium (Mount-Quick,
Daido Sangyo, Japan). Negative controls were prepared by
substituting PBS for each primary antibody. To evaluate
the expression of CK17 and CK13 in OSCC and leukopla-
kia, positively stained cells were counted in at least three
randomly selected areas at £200 magniWcations, and then,
each percentage of these positive cells was calculated as a
BIOREVO Xuorescent microscope (Keyence, Japan). The
stained sections with <5 % reactive cells were considered
to be negative, and those with more than 5 % reactive cells
were deWned as positive. The cutoV points were established
at 30 and 60 %, and 5–30 %, 30–60 %, and more than 60 %
reactive cells deWned as +, ++, and +++, respectively. The
sections were divided into two groups as follows: over
60 % positive cells were deWned as “strong” case; less than
60 % positive cells were deWned as “weak” case.
Cell lines
Five human OSCC cell lines (HSC-2, HSC-3, SQUU-A,
SQUU-B, and SAS) were used in the study. Human epithe-
lium cell line (HaCaT) was used as a calibrator. HSC-2 was
established from well-diVerentiated OSCC of mouth Xoor,
while HSC-3 and SAS were established from poorly diVerenti-
ated OSCC of tongue. SQUU-A and SQUU-B cell lines were
established from well-diVerentiated OSCC of tongue with
local recurrences. Cells were maintained in Dulbecco’s modi-
Wed Eagle’s minimum essential medium (DMEM) supple-
mented with 10 % fetal bovine serum (FBS) and incubated at
37 °C in a 5 % CO2 atmosphere. Culture media was changed
on alternate days during the experiments.
Real-time RT-PCR
Total RNA was extracted from these 6 cell lines with the
TRIzol® reagent (Invitrogen, USA). cDNAs from total
RNA were synthesized using the GeneAmp RNA PCR kit
(Applied Biosystems, USA) according to the manufac-
turer’s instructions. Real-time RT qPCR analyses were
done using QuantiTect Primar Assay (200) [Hs_KRT17
_1_SG QuantiTect Primer Assay (200) (Cat.QT00001680)
for CK17, QIAGEN]. For normalization, GAPDH was
used. The relative quantiWcation (RQ) of mRNA was
performed with STRATAGENE MX7000. The Brilliant®
SYBR® Green QPCR Master Mix (Agilent Technologies,
USA) was used for PCR ampliWcation. In total, 40 ng of
cDNA was used for each PCR in a total volume 20 l. Each
Table 2 Characteristics of 108 patients with leukoplakia
Characteristics Category Cases (%)
Gender Male 68 (63.2)
Female 40 (36.8)
Age 65> 51 (48.1)
65< 57 (53.8)




Localization of the lesion Gingiva 45 (42.5)
Tongue 44 (41.5)
Palate 10 (9.4)
Buccal mucosa 7 (6.6)
Lip 1 (0.9)
Floor of mouth 1 (0.9)123
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required by the instrument. The three-step cycle included
denaturing (94 °C, 15 s), annealing at 55 °C, and extension
at 72 °C. At the end of each PCR run, melting curve analy-
sis was performed from 60 to 95 °C for detecting non-spe-
ciWc PCR product and primer–dimer co-ampliWcation.
CK17 mRNA quantities were analyzed in duplicate, nor-
malized GAPDH as an internal control gene and expressed
in relation to mRNA from HaCaT as a calibrator. Results
are expressed as relative gene expression using the Ct
method (Livak and Schmittgen 2001).
Statistical analysis
In the real-time RT-PCR, mean value of duplicate CK17
mRNA RQs was deWned as positive if it was higher than
2.0-fold. The statistical signiWcance of the diVerences
between the groups was determined by Student’s t-test and
the chi-square test for univariate analyses. The interaction
between CK17 expression and the other variables in
patients with OSCC was determined by multivariate logis-
tic regression analysis. p values of <0.05 were considered
to be signiWcant.
Results
Immunohistochemical analyses of CK17 and CK13 
expression in OSCC
A representative case of CK17 and CK13 expressions is
shown in Fig. 1. CK17 and CK13 were predominantly
expressed in the cellular cytoplasm. In well-diVerentiated
OSCC, CK17 was strongly expressed in the majority of
tumor cells. In the cancer nest, CK17 was expressed in the
inner layers and not expressed in the outer layers (Fig. 1d).
In moderately diVerentiated OSCC, CK17 was weakly
expressed in the majority of tumor cells (Fig. 1e). In poorly
diVerentiated OSCC, CK17 was absent in the majority of
tumor cells but expressed in a few of tumor cells (Fig. 1f).
CK13 was detected in three of the 105 OSCCs (Fig. 1). In
these cases, CK13 was expressed in the center of cancer
pearls in well-diVerentiated OSCC. There were no signiW-
cant diVerences between CK13 expression and clinicopath-
ological variables (data not shown).
CK17 was detected in 101 of the 105 OSCC cases
(96.2 %). The “strong” cases with over 60 % reactive cells
were 23 of all 72 well-diVerentiated OSCCs (31.9 %). The
“strong” case was one of all 33 moderately and poorly diVer-
entiated OSCCs (3.0 %). CK17 was signiWcantly expressed in
well-diVerentiated OSCC compared to moderately and poorly
diVerentiated OSCC (p < 0.01, chi-square test; Table 3),
though there were no signiWcant diVerences for other clinical
variables (Table 3). All variables were further analyzed in a
multivariate logistic regression model. The result of the analy-
sis showed that the OSCC diVerentiation was the signiWcant
factor of CK17 “strong” cases (p < 0.01, multivariate logistic
regression analysis; Table 3). Gender, age, alcohol, smoking,
TNM classiWcation, and localization of the lesions were not
signiWcant (Table 3).
A representative case of CK17 expression in moderately
diVerentiated OSCC is shown in Fig. 2. CK17 was mark-
edly expressed in the dysplastic epithelium adjacent to the
tumor, while CK17 was not completely expressed in the
normal oral epithelium (Fig. 2d). In the cancer nest, CK17
was obviously expressed except for the outer layer and the
center of cancer pearl (Fig. 2e). In the invasion front of the
tumor, CK17 was absent in the inWltrating cells (Fig. 2f).
Immunohistochemical analyses between CK17 and CK13 
in leukoplakia and normal oral epithelium
CK17 was locally expressed in prickle cell layer of leuko-
plakia, while it is not expressed in normal oral epithelium
(Fig. 3). CK17 was detected in 55 of the 108 leukoplakias
(50.9 %). CK17 was detected in 19 of all 34 dysplastic leu-
koplakias (55.9 %) and 36 of all 74 hyperplastic leukoplak-
ias (non-dysplasia) (48.6 %). The “strong” cases were 8 of
the 34 dysplastic leukoplakias (23.5 %); on the other hand,
the “strong” cases were 3 of the 74 hyperplastic leukoplak-
ias (4.0 %). CK17 was signiWcantly expressed in dysplastic
leukoplakias compared to hyperplastic leukoplakias
(p < 0.01, chi-square test; Table 4).
CK13 was expressed in prickle cell layer of the epithe-
lium. CK13 was detected in all 10 normal oral epitheliums
(Fig. 3). CK13 was detected in 63 of the 108 leukoplakias
(58.3 %). CK13 was detected in 11 of the 34 dysplastic leu-
koplakias (32.4 %) and 52 of the 74 hyperplastic leukoplak-
ias (70.3 %). The “strong” cases were not observed in
dysplastic leukoplakias (0 %); on the other hand, the
“strong” cases were 23 of the 74 hyperplastic leukoplakias
(31.1 %). CK13 was signiWcantly expressed in hyperplastic
leukoplakia compared to dysplastic leukoplakia (p < 0.01,
chi-square test; Table 4).
In the comparison between the percentage of CK17-pos-
itive cases and that of CK13-positive cases in normal oral
epithelium, hyperplastic leukoplakia, dysplastic leukopla-
kia, and OSCC, that of CK17 was 0/10 (0 %), 35/74
(48.6 %), 18/34 (54.5 %), and 101/105 (96.2 %), respec-
tively, while that of CK13 was 10/10 (100 %), 52/74
(70.3 %), 11/34 (32.4 %), and 3/105 (2.9 %), respectively.
Indeed, the percentage of CK17-positive cases elevated
gradually in accordance with dysplastic leukoplakia and
OSCC, while the percentage of CK13-positive cases
declined gradually in accordance with dysplastic leukopla-
kia and OSCC (Fig. 4). Moreover, dysplastic leukoplakias123
J Cancer Res Clin Oncol (2012) 138:1299–1310 1303were observed in 8 of the 11 cases of CK17 “strong” and
CK13 “weak”. In contrast, hyperplastic leukoplakias were
observed in all 23 CK17 “weak” and CK13 “strong” cases
(p < 0.01, chi-square test; Table 5).
Figure 5 shows a representative case with the clear bor-
der in the leukoplakia due to the expression of CK17 and
CK13. CK17 was clearly expressed in dysplastic leukopla-
kia, while CK13 was disappeared. On the other hand, CK17
was absent in hyperplastic leukoplakia, while CK13 was
clearly expressed. These reciprocal expressions of CK17
and CK13 were obvious at the interface between dysplastic
and hyperplastic leukoplakia.
Expression of CK17 mRNA in OSCC cell lines
The relative expression of CK17 mRNA in HSC-2 (RQ;
29.3 § 4.4) was signiWcantly higher than in HSC-3 (RQ;
21.1 § 5.7) and SAS (RQ; 14.7 § 3.2) (p < 0.05, Student’s
t-test; Fig. 6). Moreover, the relative expression of CK17
mRNA in SQUU-A (RQ; 23.7 § 3.9) was signiWcantly
higher than in SQUU-B (RQ; 6.0 § 0.8) (p < 0.05,
Student’s t-test; Fig. 6). The relative expression of CK17
mRNA in HaCaT was signiWcantly lower than in the others
(RQ; 1.1 § 0.2) (p < 0.01, Student’s t-test; Fig. 6).
Discussion
The carcinogenesis mechanism of OSCC is very complex,
and a wider range of CKs is expressed in OSCC (Wetzels
et al. 1992). CK17 may play an important role in the diag-
nosis of OSCC, since several studies have reported that the
over-expression of CK17 could be detected in malignant
tissues compared to normal tissues in squamous cell carci-
Fig. 1 Immunohistochemical staining of CK17 and CK13 in OSCC.
Serial sections were stained with HE (a, b, c) anti-CK17 antibody
(d, e, f), and anti-CK13 antibody (g, h, i), and each representative case
is shown here. In well-diVerentiated OSCC, CK17 was strongly
expressed in the majority of tumor cells and was strongly expressed in
the inner of cancer nest (d). In moderately diVerentiated OSCC, CK17
was weakly expressed in the majority of tumor cells (e). In poorly
diVerentiated OSCC, CK17 was not expressed in the majority of tumor
cells (f). CK13 was not expressed in most of OSCC cases (g–i).
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2004; Ikeda et al. 2008), larynx (Cohen-Kerem et al. 2004),
and esophagus (Takahashi et al. 1995; Luo et al. 2004).
Our immunohistochemical results indicate the signiW-
cant percentage of CK17 expression in OSCC. This is in
harmony with the detection of CK17 in breast carcinoma by
immunohistochemical staining and microarray analyses
(van de Rijn et al. 2002). Moreover, CK17 mRNA is sig-
niWcantly over-expressed compared to CK19 mRNA and
CK20 mRNA in OSCC (Toyoshima et al. 2009). Further-
Table 3 Uni- and multivariate analyses for association between CK17 expression and clinicopathological variables in 105 patients with OSCC
a CK17 was detected by immunohistochemical staining, and the degree of expression was estimated as described in the “Materials and Methods”
b The number of cases is indicated
c The histological grade of diVerentiation was determined according to the criteria of WHO
d The histological grade of tumor invasion was determined according to Yamamoto and Kohama’s criteria
e The clinical stages were determined according to the International Union Against Cancer (UICC)
OR odds ratio, CI conWdence interval
Variables CK17 expressiona Univariate analysis Multivariate analysis
“Weak”b “Strong” OR (95% CI) p values OR (95% CI) p values
Gender
Male 42 11 Reference – Reference –
Female 39 13 0.786 (0.31–1.96) 0.605 0.97 (0.26–3.47) 0.959
Age
65> 45 16 Reference – Reference –
65< 36 8 0.63 (0.23–1.59) 0.335 0.63 (0.17–2.27) 0.480
Alcohol
Yes 41 15 Reference – Reference –
No 38 11 1.14 (0.45–3.02) 0.776 3.26 (0.63–19.23) 0.160
Smoking
Yes 36 12 Reference – Reference –
No 43 14 0.80 (0.31–2.01) 0.632 0.46 (0.09–2.25) 0.332
DiVerentiationc
Well 49 23 Reference – Reference –
Moderate + Poor 32 1 15.02 (2.93–275.21) 0.009 44.65 (4.94–1786.55) 0.001
T
1+2 68 20 Reference – Reference –
3+4 13 4 0.95 (0.29–3.68) 0.943 4.75 (0.23–183.39) 0.319
N
Positive 14 6 Reference – Reference –
Negative 67 18 1.59 (0.51–4.61) 0.401 4.20 (0.17–197.74) 0.386
Mode of invasiond
1 8 1 Reference – Reference –
2 16 5 0.40 (0.02–3.07) 0.437 0.69 (0.03–7.74) 0.783
3 36 13 0.35 (0.02–2.16) 0.339 0.42 (0.02–3.48) 0.456
4C 15 4 0.47 (0.02–3.88) 0.528 0.32 (0.01–5.11) 0.433
4D 6 1 0.75 (0.03–21.63) 0.849 0.47 (0.01–21.05) 0.677
Clinical stagee
I 35 7 Reference – Reference –
II 23 10 0.46 (0.15–1.37) 0.163 0.37 (0.09–1.45) 0.155
III 7 1 1.40 (0.20–28.28) 0.762 1.90 (0.03–320.93) 0.782
IV 16 6 0.53 (0.15–1.90) 0.324 0.60 (0.01–61.35) 0.823
Localization of the lesion
Tongue 49 14 Reference – Reference –
Gingiva 14 9 0.44 (0.16–1.26) 0.122 0.24 (0.04–1.13) 0.072
Others 18 1 5.14 (0.92–96.50) 0.126 4.87 (0.61–111.50) 0.147123
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OSCC with dysplasia, cancer 
nests, and inWltrating cells. Seri-
al sections were stained with HE 
(A, a–c) and anti-CK17 anti-
body (B, d–f). High-magniWca-
tion views of selected areas are 
shown (a–f). CK17 was mark-
edly expressed in dysplasia, 
while not in normal epithelium 
(d). CK17 was obviously 
expressed in the inner layer of 
cancer nest, while not in the 
outer (e). CK17 was absent in 
the inWltrating cells (f). (Original 
magniWcation £40, scale bars 
200 m)123
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array analyses in OSCC compared to normal oral
epithelium (Ye et al. 2008). In the view of these reports,
CK17 is markedly expressed in malignant tissue and thus
could be a diagnostic marker of OSCC. The results of
CK17 indicate the signiWcant expression in well-diVerenti-
ated OSCC and the decreasing expression in moderately
and poorly diVerentiated OSCC. This is in disharmony with
the CK17 expression in the most of all OSCCs despite clin-
icopathological variables, considered as a discriminating
marker of OSCC (Wei et al. 2009). But the number of cases
was too small for a statistical evaluation, since only 30
OSCCs were examined in the study. Therefore, CK17
could be a precise candidate for a diagnostic marker of
well-diVerentiated OSCC.
Focusing on the diVerentiation of OSCC cell individual,
our results show that CK17 is not expressed in the outer
layer of cancer nest in well-diVerentiated OSCC and inWl-
trating OSCC cells in poorly diVerentiated OSCC. This is
in line with the absence of CK17 expression in the basal
area of carcinoma in situ and the outer layer of cancer nest
in OSCC (Mikami et al. 2011). It has been suggested that
the outer layer of cancer nest is considered as poorly diVer-
entiated keratinocyte, since this area is the counterpart of
basal and parabasal cells in normal oral epithelium (Bloor
et al. 2000; Smedts et al. 1992). In addition, since poorly
diVerentiated OSCC has few well-diVerentiated keratino-
cytes and poorly diVerentiated keratinocytes are observed
at the invasive front (Willen et al. 1975), inWltrating OSCC
cells could be also considered as poorly diVerentiated kerat-
inocyte. Therefore, CK17 could be considered as a speciWc
marker of well-diVerentiated OSCC cells. Since poorly
diVerentiated OSCC has poor outcome because of high
malignancy (Pekkola-Heino et al. 1991), it might be possi-
ble that CK17 is not strongly expressed in high malignancy
of OSCC.
Fig. 3 Immunohistochemical staining of CK17 and CK13 in the nor-
mal oral epithelium and dysplastic and hyperplastic leukoplakias.
Serial sections were stained with HE (a–c), anti-CK17 antibody (d–f),
and anti-CK13 antibody (g–i), and each representative case is shown
here. CK17 was not expressed in normal oral epithelium and hyper-
plastic leukoplakia (d, e). CK17 was markedly expressed (f) in dys-
plastic leukoplakia. CK13 was expressed in normal oral epithelium and
hyperplastic leukoplakia (g, h) and not expressed in dysplastic leuko-
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expression of CK17 in mildly, moderately, and severely
dysplastic leukoplakia. This conXicts with the absence of
CK17 in mildly and moderately dysplastic leukoplakia
(Mikami et al. 2011), but no severely dysplastic leukopla-
kia was examined in the study. On the other side, our
results are compatible with the expression of CK17 mRNA
in severely dysplastic leukoplakia (Ohkura et al. 2005).
Moreover, CK17 is expressed in mildly, moderately,
severely dysplasia of uterine cervix (Martens et al. 2004).
Indeed, a marker of the premalignant lesion is important to
predict the malignant transformation. Nevertheless, CK17
is expressed in a portion of dysplastic leukoplakias and thus
not enough to diagnose individually premalignant lesion. In
contrast, CK13 is coordinately expressed in normal oral
epithelium and disappeared consistently in dysplastic leu-
koplakia and OSCC in the view of our results. Therefore,
combination of CK17 and CK13 might be a useful marker
to diagnose premalignant lesion with high potential of
transformation. In addition, over-expression of CK17 and
absence of CK13 might be associated with malignant trans-
formation. OSCC tissues change their histological charac-
ters and express various CKs (Wetzels et al. 1992). These
pathological changes involve the terminally diVerentiating
cell compartment, but it is still unclear about correlation
between the changes and the gene expressions of CKs
(Debus et al. 1984; Morgan et al. 1987; Vigneswaran et al.
1989; Vaidya et al. 1989). Further studies are needed to
clarify what operates to CKs genes.
Real-time RT-PCR results indicate that the quantity of
CK17 mRNA in HSC-2 derived from well-diVerentiated
OSCC is signiWcantly higher than that in HSC-3 and SAS
derived from poorly diVerentiated OSCC. This conXicts
with the detection of CK17 mRNA in OSCC cell lines by
Table 4 Association between CK17 and CK13 expression and clinicopathological variables in 108 patients with leukoplakia
a CK17 and CK13 were detected by immunohistochemical staining, and the degree of expression was estimated as described in the “Materials and
Methods”
b The number of cases is indicated
c Statistical signiWcance of the association was determined by the chi-square test
d The histological degree of dysplasia was determined according to the criteria of WHO
NS not signiWcance
Variables Category Number 
of casesb
CK17 expression in leukoplakiaa SigniWcancec CK13 expression in leukoplakiaa SigniWcancec
– + ++ +++ – + ++ +++
Gender Male 68 37 4 17 10 30 18 6 14
Female 40 16 3 20 1 NS 15 9 7 9 NS
Age 65> 51 24 5 18 4 24 10 7 10
65< 57 29 2 19 7 NS 21 17 6 13 NS
Degree 
of dysplasiad
Non-dysplasia 74 38 7 26 3 22 19 10 23
Mild 20 9 0 7 4 14 6 0 0
Moderate 8 2 0 3 3 4 2 2 0
Severe 6 4 0 1 1 p < 0.01 5 0 1 0 p < 0.01
Localization 
of the lesion
Gingiva 45 28 3 14 0 19 10 6 10
Tongue 44 20 2 12 10 17 12 5 10
Palate 10 1 1 8 0 3 3 2 2
Buccal mucosa 7 4 0 2 1 4 2 0 1
Lip 1 0 0 1 0 1 0 0 0
Floor of mouth 1 0 1 0 0 NS 1 0 0 0 NS
Table 5 Correlation between CK17 and CK13 expression in 34 patients with leukoplakia
a The histological degree of dysplasia was determined according to the criteria of WHO
b Statistical signiWcance of the association was determined by the chi-square test
c CK17 and CK13 were detected by immunohistochemical staining, and the degree of expression was estimated as described in the “Materials and
Methods”
Dysplasiaa Non-dysplasia Total SigniWcanceb
CK17 “strong”c/CK13 “weak” 8 3 11
CKlT “weak”/CK13 “strong” 0 23 23 p < 0.01123
1308 J Cancer Res Clin Oncol (2012) 138:1299–1310real-time RT-PCR despite their diVerentiation (Ohkura
et al. 2005). In fact, CK17 is synthesized at the stage of cell
fate speciWcation within developing skin epithelium
(McGowan et al. 2002). Moreover, onset of CK17 expres-
sion reXects the determination of the lineage in skin epithe-
lium (McGowan and Coulombe 1998). Furthermore, CK17
is not expressed in the basal cell, while it is expressed in the
suprabasal cells that have been already diVerentiated. This
indicates that there is a diVerence of CK17 expression
pattern according to the cell diVerentiation.
CK17 mRNA quantity was signiWcantly higher in
SQUU-A than in SQUU-B, though both are derived from
well-diVerentiated OSCC. The in vitro formation of inter-
mediate Wlaments is prominently observed in SQUU-A
compared to SQUU-B (Morifuji et al. 2000). Furthermore,
piling up of SQUU-A cells was partially seen, whereas
Fig. 4 Percentage of CK17- and CK13-positive cases in normal oral
epithelium, leukoplakia, and OSCC. The percentages of CK17-posi-
tive cases were 0/10 (0 %), 35/74 (48.6 %), 18/34 (54.5 %), and 101/
105 (96.2 %), respectively, while the percentages of CK13-positive
cases were 10/10 (100 %), 52/74 (70.3 %), 11/34 (32.4 %), and 3/105
(2.9 %), respectively, in normal oral epithelium, hyperplastic leukopla-






















































Fig. 5 Immunohistochemical 
staining of CK17 and CK13 in 
the border between dysplastic 
leukoplakia and hyperplastic 
leukoplakia. CK17 was clearly 
expressed in dysplastic leuko-
plakia, while it was disappeared 
in hyperplastic leukoplakia (a). 
CK13 was disappeared in dys-
plastic leukoplakia, while it was 
clearly expressed in hyperplastic 
leukoplakia (b). A reciprocal 
expression of CK17 and CK13 
could be found between the two 
diVerent lesions (original magni-
Wcation£100, scale bars 
100 m)
Fig. 6 Relative expression of CK17 mRNA in OSCC cell lines and
human epithelium cell line. The relative expression of CK17 mRNA in
HSC-2 was signiWcantly higher than in HSC-3 and SAS. Moreover, the
relative expression of CK17 mRNA in SQUU-A was signiWcantly
higher than in SQUU-B. The relative expression of CK17 mRNA in
HaCaT was signiWcantly lower than the others. Statistical analyses




















* p < 0.05
** p < 0.01
** 123
J Cancer Res Clin Oncol (2012) 138:1299–1310 1309SQUU-B cells developed multiple layers throughout. Com-
bined with the ability of muscle invasion and cervical
lymph node metastasis in vivo, SQUU-B resembles to
HSC-3 closely, because HSC-3 also has the ability (Kawa-
hara et al. 1995). Therefore, SQUU-B might have feature of
poorly diVerentiated OSCC compared to SQUU-A.
In conclusion, CK17 expression could be associated
with the diVerentiation and the malignancy of OSCC. A
combination pattern of CK17/CK13 might be a suitable
marker of malignant transformation.
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